Back to all news

FDA Clears First AI Tool for 5-Year Breast Cancer Risk Prediction from Mammograms

FDA Clears First AI Tool for 5-Year Breast Cancer Risk Prediction from Mammograms

Clairity Breast becomes the first FDA-authorized AI software to predict five-year breast cancer risk using routine mammography images.

Key Details

  • 1FDA grants de novo authorization to Clairity Breast, developed by Boston-based Clairity.
  • 2The AI tool analyzes mammogram images for subtle features correlated with future cancer risk.
  • 3Unlike traditional models, Clairity Breast does not require age or genetic data.
  • 4The system was trained on millions of mammogram images linked to five-year outcomes.
  • 5Clairity Breast delivers validated risk scores to radiologists through standard clinical systems.
  • 6Commercial launch is targeted for the end of 2025.

Why It Matters

This breakthrough FDA authorization marks a new era in preventive oncology by enabling earlier risk identification using only imaging, potentially improving precision prevention and patient outcomes in breast cancer care.
Radiology Business

Source

Radiology Business

View all from this source

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.